Shanghai Pharmaceuticals Holding Stock Probability Of Bankruptcy
| SHPMY Stock | USD 7.88 0.32 3.90% |
Shanghai |
Shanghai Pharmaceuticals Holding Company probability of bankruptcy Analysis
Shanghai Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Shanghai Pharmaceuticals Probability Of Bankruptcy | Less than 10% |
Most of Shanghai Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Shanghai Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Shanghai Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Shanghai Pharmaceuticals Holding financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Shanghai Pharmaceuticals Holding has a Probability Of Bankruptcy of 10.0%. This is 76.9% lower than that of the Healthcare sector and 54.0% lower than that of the Medical Distribution industry. The probability of bankruptcy for all United States stocks is 74.89% higher than that of the company.
Shanghai Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics of similar companies.Shanghai Pharmaceuticals is currently under evaluation in probability of bankruptcy category among its peers.
Shanghai Fundamentals
| Return On Equity | 0.1 | |||
| Return On Asset | 0.0281 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.04 % | |||
| Current Valuation | 9.42 B | |||
| Shares Outstanding | 739.51 M | |||
| Price To Earning | 5.42 X | |||
| Price To Book | 0.69 X | |||
| Price To Sales | 0.04 X | |||
| Revenue | 215.82 B | |||
| Gross Profit | 28.41 B | |||
| EBITDA | 10.73 B | |||
| Net Income | 5.09 B | |||
| Cash And Equivalents | 37.3 B | |||
| Cash Per Share | 50.45 X | |||
| Total Debt | 7.16 B | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 1.40 X | |||
| Book Value Per Share | 89.51 X | |||
| Cash Flow From Operations | 5.06 B | |||
| Earnings Per Share | 1.22 X | |||
| Price To Earnings To Growth | 2.52 X | |||
| Number Of Employees | 47.06 K | |||
| Beta | 0.33 | |||
| Market Capitalization | 9.2 B | |||
| Total Asset | 163.44 B | |||
| Retained Earnings | 14.62 B | |||
| Working Capital | 19.59 B | |||
| Current Asset | 61.39 B | |||
| Current Liabilities | 41.8 B | |||
| Z Score | 1.6 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.15 % | |||
| Net Asset | 163.44 B | |||
| Last Dividend Paid | 0.42 |
About Shanghai Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Shanghai Pink Sheet Analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.